Medical Care Technologies Inc. Unveils Breakthrough AI for Early Melanoma Detection

Rhea-AI Summary

Medical Care Technologies (OTC:MDCE) has unveiled a groundbreaking AI platform for early melanoma detection. The technology leverages deep learning algorithms trained on millions of dermatoscopic and clinical images to analyze key melanoma risk factors including asymmetry, border irregularities, color variations, diameter, and evolution monitoring.

The AI system creates longitudinal profiles of moles and lesions, flagging anomalies before progression. This advancement is particularly significant as melanoma, while representing only 1% of skin cancers, causes the majority of skin cancer deaths. When detected early, melanoma survival rates exceed 95%.

Positive

• AI platform enables early detection of melanoma before clinical obviousness
• Technology leverages deep learning trained on millions of dermatoscopic images
• System provides longitudinal monitoring and automated anomaly detection
• Solution brings professional-grade diagnostic capabilities into home settings

Negative

• Technology is still new and unproven in real-world settings
• No regulatory approval status mentioned in the announcement

MESA, ARIZONA / ACCESS Newswire / September 18, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a leader in AI-powered preventive healthcare, today announced a major advancement in dermatology: an artificial intelligence platform designed to revolutionize the early detection of melanoma, the deadliest form of skin cancer.

Melanoma accounts for only 1% of skin cancers but causes the majority of skin cancer deaths worldwide. Early intervention is critical-when caught in its initial stages, melanoma survival rates exceed 95%. MDCE's AI platform could dramatically improve the ability to identify melanomas before they are clinically obvious.

How the Technology Works

The system leverages deep learning algorithms trained on millions of dermatoscopic and clinical images to analyze key melanoma risk factors:

• Asymmetry in lesion structure

• Border irregularities at the cellular level

• Color variegation, including detection of subtle pigment changes invisible to the human eye

• Diameter tracking over time

• Evolution monitoring, comparing each lesion against a patient's personal historical baseline

By building a longitudinal profile of every mole and lesion, the AI flags anomalies and recommends triage before progression, transforming skin self-checks into a powerful early warning system.

"Melanoma's danger lies in its ability to grow undetected until it's too late," said Marshall Perkins, CEO of MDCE. "Our AI technology brings an AI powered diagnostic tool into the home, empowering patients and clinicians with earlier, more precise insights that can save lives."

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC: MDCE) is committed to advancing AI-driven preventive healthcare, from mental health and neurological monitoring to dermatological and ocular disease detection.

Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com

---

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What is Medical Care Technologies' (MDCE) new AI melanoma detection technology?

MDCE has developed an AI platform that analyzes skin lesions using deep learning algorithms, monitoring factors like asymmetry, border irregularities, color changes, diameter, and evolution to detect melanoma early.

How effective is early melanoma detection for survival rates?

According to MDCE's announcement, when melanoma is caught in its initial stages, survival rates exceed 95%. Early detection is critical as melanoma causes the majority of skin cancer deaths despite representing only 1% of skin cancers.

What features does MDCE's AI melanoma detection system analyze?

The system analyzes five key factors: 1) lesion asymmetry, 2) border irregularities, 3) color variegation, 4) diameter tracking, and 5) evolution monitoring against historical baselines.

How does MDCE's AI melanoma detection platform work?

The platform uses deep learning algorithms trained on millions of dermatoscopic and clinical images to create longitudinal profiles of moles and lesions, automatically flagging anomalies and recommending triage before progression.

Who is leading Medical Care Technologies' AI melanoma detection initiative?

The initiative is led by Marshall Perkins, CEO of Medical Care Technologies (MDCE).